< BACK Call for Workshop Papers: AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact May 16, 2025 A joint workshop by iPROLEPSIS and AI-PROGNOSIS at IEEE HealthCom 2025 in Abu Dhabi, focusing on AI-enabled Digital Health Tools for Non-Communicable Diseases The iPROLEPSIS and AI-PROGNOSIS projects are co-organising a workshop titled: “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact” as part of the IEEE HealthCom 2025 conference , taking place on 21–23 October 2025 in Abu Dhabi, United Arab Emirates. More information: https://healthcom2025.ieee-healthcom.org/program/ai-enabled-digital-health-tools-non-communicable-diseases-concepts-impact We invite authors to submit original research, position papers, or case studies with practical insights. Topics of interest include (but are not limited to): Predictive models for early detection, risk assessment, and prognosis of NCDs Digital biomarkers and wearable sensors for NCDs Machine learning for personalized treatment, disease management, and precision medicine AI in remote care, mHealth, and telemedicine for NCDs Regulatory and ethical considerations in AI-enabled software as medical device Data quality, fairness, and explainability in AI health applications User-centered design in AI-enabled health technology for chronic conditions Translational pathways from research prototypes to scalable digital health solutions The workshop aims to feature 10 selected papers. Important dates: Workshop paper submission July 1, 2025 Acceptance notifications August 15, 2025 Camera Ready papers August 30, 2025 For any questions, please contact: Dr. Vasileios Charisis , Aristotle University of Thessaloniki, Greece – vaschar@auth.gr Dr. Stelios Hadjidimitriou , Aristotle University of Thessaloniki, Greece – shadjidim@ece.auth.gr HealthCom 2025_Call for WS papers_Digital Health Tools for NCDs .pdf Download PDF • 181KB iPROLEPSIS_Call for workshop papers.png iPROLEPSIS_Call for workshop papers.png 1/1 PREVIOUS NEXT

< BACK Innovative Digital Solutions for Psoriatic Arthritis: A Spotlight on the iPROLEPSIS Project by Prof. Leontios Hadjileontiadis Feb 14, 2024 Empowering Patients, Pioneering Solutions, and Bridging Gaps in Psoriatic Arthritis Knowledge Prof. Leontios Hadjileontiadis, the coordinator of the iPROLEPSIS project, shares how the iPROLEPSIS project addresses psoriatic arthritis research . iPROLEPSIS aims to identify triggers behind the transition from psoriasis to psoriatic arthritis, employing digital models and everyday devices like smartphones and smartwatches to understand disease dynamics. Beyond research, iPROLEPSIS introduces practical solutions such as biAURA for pain relief through sound and serious games targeting exercise, emotion, nutrition, and pain management. Collaborating with 15 partners, including patient advocates, iPROLEPSIS adopts a co-creation approach , bridging technological innovation with real-world healthcare practices. Focusing on predictive and preventive healthcare, iPROLEPSIS strives to fill the knowledge gap surrounding psoriatic arthritis, transforming the research landscape. Watch the full interview: https://www.youtube.com/watch?v=HpiUosn6ETQ leontios_edited.jpg leontios_edited.jpg 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Research Presented at the 60th ESCI Annual Scientific Meeting Jun 15, 2026 From Sensors to Predictive Algorithms: Real-World Digital Biomarkers of Disease Activity in Psoriatic Arthritis On 3–5 June 2026, the European Society for Clinical Investigation (ESCI) held its 60th Annual Scientific Meeting at NOVA Medical School in Lisbon, Portugal. The meeting, themed "Research in action: building healthier futures", brought together clinical researchers from across Europe. iPROLEPSIS was represented at the meeting with a presentation titled "From Sensors to Predictive Algorithms: Real-World Digital Biomarkers of Disease Activity in Psoriatic Arthritis" , delivered by Cátia F. Gonçalves, PhD (SPR). The presentation introduced the PDPID study – a prospective, real-world observational cohort study conducted across four European countries as part of the iPROLEPSIS project. The study investigates the use of smartphone and smartwatch sensor data, combined with patient-reported outcomes and clinical assessments, to develop digital biomarkers capable of monitoring disease activity and predicting flares in psoriatic arthritis. Cátia-Gonçalves-60th-ESCI-2026-final (1) .pdf Download PDF • 1.57MB 11.png 2.png 14.png 11.png 1/14 PREVIOUS NEXT

< BACK Patient Voices in Research: Elaine’s Das Cheppo Journey with iPROLEPSIS Mar 4, 2025 A Patient’s Perspective: Elaine’s Journey with iPROLEPSIS Elaine Das Cheppo has been living with psoriatic arthritis for 25 years . Like many others, her diagnosis was delayed, making treatment more challenging in the early years. When her rheumatologist asked if she would like to take part in the iPROLEPSIS project , she did not hesitate. "I struggled in the beginning to understand why I was experiencing so much joint pain. By participating in this study, I hope to help future generations get a diagnosis faster than I did." The Role of Patient Partners in iPROLEPSIS Elaine is a patient partner in iPROLEPSIS, working alongside researchers to improve psoriatic arthritis care. She finds the co-creation sessions particularly insightful, offering her a behind-the-scenes look at how digital health solutions are developed. "It’s interesting to see how new technology is being used to improve diagnosis and treatment. These innovations could help people avoid unnecessary doctor visits and manage their condition more effectively." A Renewed Sense of Purpose For Elaine, being part of iPROLEPSIS is not just about contributing to research—it’s also about personal fulfillment . "For someone who has been retired for quite some time, it’s rewarding to have a new goal and interest in life. Being part of this project gives me a way to make a difference." Watch Elaine’s full story here: https://www.youtube.com/watch?v=BB0udK7B57w 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at Faculdade de Motricidade Humana PhD Seminar Dec 4, 2025 Lecture on recent findings shared with PhD students On 20 November 2025 , iPROLEPSIS was presented at Faculdade de Motricidade Humana (FMH) during the PhD seminar “Métodos de Investigação Avançada em Motricidade Humana”. Sofia Balula Dias spoke to more than 20 PhD students , presenting key findings from the project’s most recent publications and ongoing research on psoriatic arthritis. The session was an opportunity to share current scientific work and answer questions from the students. Slide1.JPG Slide2.JPG Slide8.JPG Slide1.JPG 1/8 PREVIOUS NEXT

< BACK Highlights from IFPA 2024 Jun 28, 2024 iPROLEPSIS at IFPA 2024 The 7th World Psoriasis & Psoriatic Arthritis Conference, held on June 27-29, 2024, brought together leading experts and researchers to discuss the latest advancements in psoriasis and psoriatic arthritis. Dr Laura Coates from the University of Oxford discussed the potential to prevent psoriatic arthritis, including the work being done in iPROLEPSIS and HIPPOCRATES IMI. 1/6 PREVIOUS NEXT

< BACK Highlights from PETRA 2024 Jul 1, 2024 The iPROLEPSIS Exergames Introduced at PETRA 2024 The iPROLEPSIS Exergames were introduced and received very positively by the audience at PETRA 2024, a scientific interdisciplinary conference held on 26-28 June 2024 in Crete, Greece. Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes Abstract: Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Here, within the Horizon Europe iPROLEPSIS project that targets Psoriatic Arthritis (PsA), we describe the design process of Exergames to address PsA symptoms, including morning stiffness, impaired finger/hand and wrist functionality, and motor asymmetry. From a methodological point of view, the storyboarding technique was adopted to facilitate the visualization of the proposed Exergame scenarios, including the graphical user interface, interactive game elements, narratives, characters, and contexts related to the PsA condition. This approach has been implemented within an agile game development methodology, which includes gathering feedback early on to iteratively refine both the game ideas and prototype. Informed by the results of the game design via two agile sessions incorporating 25 participants (PsA patients, clinicians, technology developers, facilitators/observers), the current efforts are focused on developing the game prototypes and corresponding mock-ups, preparing them for upcoming clinical validation trials. The Exergames development lays the groundwork for an innovative framework to improve gross and fine motor symptoms in PsA patients. This framework could inform healthcare providers and policymakers about its potential inclusion in routine PsA management. Read the full publication: https://dl.acm.org/doi/10.1145/3652037.3663939 1/3 PREVIOUS NEXT

< BACK iPROLEPSIS Sensorimotor Games Presented at DSAI 2024 Nov 20, 2024 Innovative digital games designed to support people with Psoriatic Arthritis presented at an international ICT conference. The iPROLEPSIS project coordinator, Prof. Leontios Hadjileontiadis, presented the iPROLEPSIS Sensorimotor Games at the 11th International Conference on Software Development and Technologies for Enhancing Accessibility and Fighting Info-exclusion (DSAI 2024) . The conference was held from 13–15 November at Khalifa University in Abu Dhabi, United Arab Emirates (UAE). The Sensorimotor Games are interactive digital applications designed for more than just entertainment. They combine enjoyment with skills training, social impact, and health improvement. As part of a personalised game suite, these games aim to support people living with Psoriatic Arthritis (PsA), offering a unique approach to enhancing their quality of life. DSAI is a leading international forum focused on accessible and usable Information and Communication Technologies (ICT). The conference provided an excellent platform to share progress on the iPROLEPSIS project and highlight its innovative approach to digital healthcare solutions. 1/2 PREVIOUS NEXT

< BACK Unveiling the Future of Psoriatic Arthritis Care: Insights from Dr Laura Coates Mar 19, 2024 Exploring the iPROLEPSIS Project and Innovations in Digital Health Technologies for Enhanced Patient Care Dr Laura Coates , a researcher and clinician from the University of Oxford , guides through the research and clinical studies of the iPROLEPSIS project. In her own words: "It’s my pleasure to be leading all of the clinical studies within the iPROLEPSIS Consortium. We're focused on developing and testing apps and digital health technologies to enhance the care for patients with psoriatic arthritis ." Discover how these innovative tools aim to predict and manage psoriatic arthritis flares, identify at-risk individuals, and empower patients to take control of their health. Dr Coates elaborates on the various aspects of the research, including the development of apps that could foresee a flare, identify triggers, and even provide support for stress management and activity. https://www.youtube.com/watch?v=nYPtH0jb0yo Screenshot 2024-03-19 123331.png Screenshot 2024-03-19 123331.png 1/1 PREVIOUS NEXT

< BACK Advancing Psoriatic Arthritis: Rheumatologist Ilja Tchetverikov's Insights on iPROLEPSIS May 22, 2024 Exploring Innovative Approaches to Disease Management and Patient Care in Psoriatic Arthritis" Ilja Tchetverikov , a rheumatologist and project partner from the CICERO Foundation (the Netherlands), provides insights into the iPROLEPSIS project's endeavours. He emphasises the need for a deeper understanding of psoriatic arthritis , a chronic inflammatory condition impacting various body parts due to immune system disturbances. I. Tchetverikov highlights the project's focus on investigating disease progression factors and developing non-invasive measurement tools . “Everybody can measure anything, but then you have to know what you're measuring. The whole idea of the project is that we combine two strengths. One of them is providing and developing a technical solution on how to measure the disease activity. And from the other side, we are going to label the data coming in from the system, from the clinical point of view. So we will be able to say whether or not some people have a low or high level of disease activity. So it's one part of the investigation. The other part of the investigation is to see whether other factors, which are already known to influence the whole system of your human body, like stress factors and some, for instance, gut microbiome composition, can also change during the course of the disease and how they are influencing the course of the disease itself,” states Ilja Tchetverikov . Through a collaborative effort integrating clinical expertise and technical innovation, the project aims to assess disease activity levels and explore external factors accurately. https://www.youtube.com/watch?v=PcUHfHsWSVs iPROLEPSIS interview.png iPROLEPSIS interview.png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS at BIOSTEC 2026 Mar 16, 2026 Presenting iPROLEPSIS at an international forum on biomedical engineering and health technology The 19th International Joint Conference on Biomedical Engineering Systems and Technologies (BIOSTEC 2026) took place in Marbella, Spain from 2 to 4 March 2026. The event brought together researchers, technology developers, and industry representatives working in biomedical engineering and healthcare technologies. iPROLEPSIS was represented at the event by project partner PLUX. The project was presented to an international audience, helping to raise its visibility among stakeholders interested in digital health and innovative medical technologies. PLUX also highlighted the importance of multisensor biosignal acquisition and the value of combining different physiological signals to support more comprehensive health research and real-world healthcare applications. iProlepsis BIOSTEC 2.jpg 20260303_111530.jpg IMG_6609.jpg iProlepsis BIOSTEC 2.jpg 1/4 PREVIOUS NEXT

< BACK AI-Driven Early Prediction and Personalised Care | iPROLEPSIS, AI-PROGNOSIS & REBECCA Mar 3, 2026 A joint video highlighting how digital biomarkers and real-world data support patient-centred healthcare across three disease areas What happens when a disease enters someone’s life and changes everything? Millions of people live with chronic conditions that shape their daily routines – often in ways that are invisible to others. Early diagnosis, timely intervention and more effective care can make a profound difference. In a new joint video developed with support from the European Commission’s Booster initiative, the EU-funded projects iPROLEPSIS , AI-PROGNOSIS and REBECCA present a shared vision for patient-centred artificial intelligence in healthcare. The video highlights how AI and digital biomarkers can enable earlier prediction, continuous monitoring and more personalised care across three disease areas: Psoriatic arthritis (iPROLEPSIS) Parkinson’s disease (AI-PROGNOSIS) Breast cancer survivorship (REBECCA) By integrating real-world behavioural data, wearable sensor signals and patient-reported information, the projects demonstrate how complex health data can be transformed into actionable clinical insights. These AI-driven approaches aim to strengthen clinical decision-making while keeping patients at the centre of care. The video reflects the projects’ commitment to developing trustworthy, responsible and co-designed AI solutions that respond to real clinical and patient needs. Watch the video here: https://www.youtube.com/watch?v=hWu3bPzQBiA To learn more, visit: iPROLEPSIS – https://www.iprolepsis.eu AI-PROGNOSIS – https://www.ai-prognosis.eu REBECCA – https://www.rebeccaproject.eu Screenshot 2026-03-02 115452.png Screenshot 2026-03-02 115452.png 1/1 PREVIOUS NEXT